Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
| ▸ | MAPKAPK5 | Q8IW41 | 11/20 | 0.34 |
| ▸ | AURKA | O14965 | 4/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14536958 | 0.81 | AURKA (0.36) | AURKAAURKBFLT3TTK | |
| SCHEMBL14536853 | 0.79 | AURKA (0.46) | PTK6MAPKAPK5AURKAAURKBFLT3 | |
| SCHEMBL8241173 | 0.77 | AURKA (0.60) | PTK6MAPKAPK5AURKAAURKBFLT3 | |
| SCHEMBL14536830 | 0.73 | AURKA (0.37) | MAPKAPK5AURKAAURKBFLT3TTK | |
| SCHEMBL14507243 | 0.70 | EGFR (0.41) | PTK6MAPKAPK5AURKAAURKBFLT3 | |
| SCHEMBL14529900 | 0.69 | TTK (0.50) | MAPKAPK5AURKAAURKBFLT3TTK | |
| SCHEMBL12473231 | 0.69 | AURKA (0.34) | MAPKAPK5AURKAAURKBFLT3 | |
| SCHEMBL15146186 | 0.67 | FYN (0.49) | PTK6MAPKAPK5AURKAAURKBFLT3 | |
| SCHEMBL14507206 | 0.67 | TTK (0.41) | MAPKAPK5AURKAAURKBFLT3TTK | |
| SCHEMBL14537080 | 0.65 | AURKA (0.45) | MAPKAPK5AURKAAURKBFLT3TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |